PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
1.81%
Revenue growth of 1.81% vs. zero growth in Drug Manufacturers - Specialty & Generic. Walter Schloss might still want to see if it can translate into profits.
23.28%
Gross profit growth of 23.28% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight advantage that could be built upon.
119.76%
EBIT growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 11.57%. Joel Greenblatt would examine whether a unique competitive edge supports this outperformance.
119.76%
Operating income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 7.42%. Joel Greenblatt would see if unique processes drive exceptional profitability.
-0.34%
Negative net income growth while Drug Manufacturers - Specialty & Generic median is 2.53%. Seth Klarman would investigate factors dragging net income down.
5.93%
EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 3.56%. Joel Greenblatt would confirm if consistent earnings expansion underpins these gains.
7.76%
Diluted EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 3.22%. Joel Greenblatt would confirm if strong net income growth or buybacks drive outperformance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-73.67%
Negative OCF growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-24.62%
Negative FCF growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
729.33%
3Y CAGR of 729.33% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest improvement overshadowing the broader sector’s stagnation.
-5193.14%
Negative 10Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-372.30%
Negative 5Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-681.49%
Negative 3Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
1634.96%
Net income/share CAGR exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 18.98% over a decade. Joel Greenblatt might see a standout compounder of earnings.
2589.28%
5Y net income/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 15.66%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
428.42%
3Y net income/share CAGR of 428.42% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a small advantage that can be scaled further.
6077.40%
Equity/share CAGR exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 16.35% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
14361.42%
5Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 25.48%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
589.54%
3Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 17.70%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
34.59%
AR growth of 34.59% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
24.96%
Inventory growth far above Drug Manufacturers - Specialty & Generic median. Jim Chanos suspects major issues in demand forecasting or potential obsolescence risk.
0.90%
We expand assets while Drug Manufacturers - Specialty & Generic is negative. Peter Lynch sees a possible advantage if expansions align with profitable markets or a recovering cycle.
2.53%
BV/share growth of 2.53% while Drug Manufacturers - Specialty & Generic is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-1.79%
Debt is shrinking while Drug Manufacturers - Specialty & Generic median is rising. Seth Klarman might see an advantage if growth remains possible.
135.68%
We slightly increase R&D while Drug Manufacturers - Specialty & Generic is cutting. Peter Lynch sees a chance to grab market share with new offerings if ROI is managed well.
2.34%
SG&A growth of 2.34% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.